Feed AVDL
AV

Avadel Pharmaceuticals plc

AVDL · NASDAQ

$21.64 +0.00% (+$0.00)
Market Cap $2.12B
P/E Ratio -
Div. Yield -
ROE 0.33%
Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
P/S 8.55x
P/B 21.62x
P/FCF 59.99x
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
49 /100
Moderate
Net margin 0.11%
Op. margin 1.82%
FCF margin 14.25%
Quality
16 /100
Poor
ROE 0.33%
ROA 0.14%
Asset turnover 1.25x
Debt
80 /100
Low
Current ratio 2.76x
Int. coverage 0.66x
Net debt/EBITDA -4.19x
Stability
19 /100
Unstable
EPS volatility 662.55%
Profitable years 0
Beta 1.31x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o AVDL
Online

O podjetju

Avadel Pharmaceuticals plc (AVDL) is an Irish pharmaceutical company focused on the development and commercialization of medicines for the treatment of neurological and cardiovascular diseases. With a product portfolio including drugs such as FT218 and Noctiva, Avadel Pharmaceuticals aims to provide innovative therapeutic options for patients suffering from various conditions. The company emphasizes research and development of new drug formulations and treatment approaches to meet the needs of patients and the medical community. Avadel Pharmaceuticals plc (AVDL) shares could be suitable for investors looking for investments in the pharmaceutical industry with a focus on innovative therapies and drug development for neurological and cardiovascular diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Gregory J. Divis Jr.

Employees

188

Headquarters

Dublin

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.